GH Research PLC (GHRS)
- Previous Close
10.50 - Open
10.47 - Bid 10.51 x 100
- Ask 10.72 x 100
- Day's Range
10.40 - 10.75 - 52 Week Range
5.05 - 14.64 - Volume
8,567 - Avg. Volume
125,325 - Market Cap (intraday)
548.896M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.68 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.75
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
www.ghres.comRecent News: GHRS
Performance Overview: GHRS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GHRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GHRS
Valuation Measures
Market Cap
546.30M
Enterprise Value
385.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.49
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-10.95
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.72%
Return on Equity (ttm)
-15.18%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.59M
Diluted EPS (ttm)
-0.68
Balance Sheet and Cash Flow
Total Cash (mrq)
161.56M
Total Debt/Equity (mrq)
0.44%
Levered Free Cash Flow (ttm)
-21.83M